<DOC>
	<DOCNO>NCT01138111</DOCNO>
	<brief_summary>The aim study investigate whether Florbetaben ( BAY94-9172 ) positron emission tomography ( PET ) able distinguish subject mild cognitive impairment ( MCI ) progress Alzheimer 's disease ( AD ) MCI progress AD .</brief_summary>
	<brief_title>Florbetaben ( BAY94-9172 ) PET ( Positron Emission Tomography ) Imaging MCI ( Mild Cognitive Impairment ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Presence MCI define abnormal cognition objective test absence dementia significant functional loss . Absence systemic neurological disease may contribute cognitive impairment prevent followup two year . Able give write informed consent . Age &gt; /= 60 year age &gt; /= 7 year education Mini mental state examination ( MMSE ) score &lt; 24 baseline Clinical dementia rating ( CDR ) score &gt; 0.5 baseline Patients receive regular medication drug may adversely impact cognition ( e.g . tricyclic antidepressant , antipsychotic and/or large dos hypnotic anxiolytic ) Existing history cancer History severe head trauma , brain surgery intracranial hematoma permanent brain lesion Lifetime history major affective disorder , schizophrenia , schizoaffective disorder Contraindications MRI ( Magnetic resonance imaging ) Relevant history , physical imaging finding neurological disease MCI mild depression History severe anaphylactic reaction high risk allergic reaction drug Patient receive another investigational drug precede 14 day</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Florbetaben</keyword>
	<keyword>Amyloid beta-protein</keyword>
	<keyword>MCI</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>